Abstract:Background: Insomnia is more common as people age. Several common hypnotics used to treat insomnia often do not adequately alleviate sleep issues in older adults and may be associated with negative residual effects such as an increased risk of falls, cognitive impairment, automobile accidents, and lack of response to auditory stimuli. The objective of these analyses of three clinical studies was to investigate the efficacy and safety of the dual orexin-receptor antagonist lemborexant (LEM) in older adults. Methods: Study E2006-G000-304 (Study 304; NCT02783729) was a randomized, double-blind, placebo (PBO)-controlled, active-comparator trial where subjects with insomnia disorder received LEM 5 mg (LEM5), LEM 10 mg (LEM10), zolpidem tartrate extended-release 6.25 mg (ZOL), or PBO for 30 days. In crossover Study E2006-E044-106 (Study 106; NCT02583451), healthy subjects (good sleepers) received LEM 2.5 mg, LEM5, LEM10, or PBO for eight nights or zopiclone on days 1 and 8 (and PBO on days 2-7). In crossover Study E2006-A001-108 (Study 108; NCT03008447), healthy subjects received a single dose of LEM5, LEM10, PBO, or ZOL. Sleep assessments included polysomnography-based latency to persistent sleep (LPS), wake after sleep onset (WASO), WASO in the second half of the night (WASO2H), sleep efficiency, postural stability, middle-of-the-night and next-day cognitive performance, middle-of-the-night auditory awakening threshold and return-to-sleep latency, and driving performance. Results: Overall, 453 of 1006 (45%; Study 304), 24 of 48 (50%; Study 106), and 28 of 56 (50%; Study 108) subjects were aged ≥ 65 years. In Study 304, LEM decreased (improved) LPS, WASO, and WASO2H from baseline more than ZOL and PBO; subjects treated with LEM had greater increases in sleep efficiency (improved) than with ZOL or PBO. In both Studies 304 and 108, postural stability was not impaired at waketime in subjects who received LEM compared with PBO. At waketime, LEM did not impair memory compared with PBO. In Study 108, following middle-of-the-night awakening, LEM and ZOL did not affect subjects' ability to awaken to auditory stimuli; LEM did not affect tests of memory and attention. In Study 106, LEM did not impair next-day driving performance in healthy elderly compared with PBO. LEM was well tolerated in subjects aged ≥ 65 years. Conclusions: LEM provided benefits on sleep variables without next-morning residual effects in subjects aged ≥ 65 years, supporting LEM as a treatment option for older adults with insomnia. Trial registration numbers and dates of registration: Study 304: ClinicalTrials.gov identifier, NCT02783729, date of registration, 26 May 2016. Study 106: ClinicalTrials.gov identifier, NCT02583451, date of registration, 22 October 2015. Study 108: ClinicalTrials.gov identifier, NCT03008447, date of registration, 2 January 2017.

Efficacy and Safety of Zolpidem in Treatment of Primary Insomnia in Chinese Elderly: an Open, Selfcontrolled, Multicenter Study

Efficacy observation of zolpidem in improvement of sleep quality of patients received methadone maintenance treatment

A multicenter,randomized,double-blind,controlled clinical trial of domestic zaleplon for insomnia

Efficacy and Safety of Eszopiclone in 2-week Treatment of Primary Insomnia:a Randomized,Double-blind,Zopiclone-controlled Multicenter Trial

Effect and reliability of zaleplon on treatment of insomnia:a randomized,double-blind,controll study

Efficacy and Safety of Eszopiclone in the Treatment of Insomnia

The efficacy and safety of zolpidem and zopiclone to treat insomnia in Alzheimer’s disease: a randomized, triple-blind, placebo-controlled trial

Study on the Effect of Zopiclone and Eszopiclone in the Treatment of Insomniac Patients by Polysomnogram

The relationship between alertness and sleep in a population of 769 elderly insomniacs with and without treatment with zolpidem

Efficacy of Mindfulness-Based Intervention ('Mindfulness-Based Joyful Sleep') in Young and Middle-Aged Individuals with Insomnia Using a Biomarker of Inflammatory Responses: a Prospective Protocol of a Randomised Controlled Trial in China.

Clinical Evatution of Insomnia Therapy by Zaleplon

Efficacy of fluoxetine combined with psychological intervention for treatment of depressive patients with insomnia

Insomnia and the effect of zolpidem-extended-release on the sleep items of the Hamilton Rating Scale for Depression in outpatients with depression, insomnia, and suicidal ideation: Relationship to patient age

Efficacy and safety of Dimdazenil in adults with insomnia disorder: results from a multicenter, randomized, double-blind, placebo-controlled phase III trials

[Effects of paroxetine with or without zolpidem on depression with insomnia: a multi-center randomized comparative study].

Randomized controlled clinical trial on( + ) zopiclone versus zopiclone in the treatment of insomnia

Efficacy of Zhumian Tang formula granules combined with eszopiclone for the treatment of poor sleep quality: a multi-center, randomized controlled, superiority trial

Efficacy, acceptability, and tolerability of all available treatments for insomnia in the elderly: a systematic review and network meta-analysis

Commercial Chinese polyherbal preparation Zao Ren An Shen prescription for primary insomnia: a systematic review with meta-analysis and trial sequential analysis

Efficacy and tolerability of pharmacological treatments for insomnia in adults: A systematic review and network meta-analysis

Efficacy and safety of insomnia treatment with lemborexant in older adults: analyses from three clinical trials